Thrombogenics N.V. | Ownership
Companies that own Thrombogenics N.V.
Dimensional Fund Advisors LP
434,223
1.13%
49,972
0%
04/30/2018
Norges Bank Investment Management
321,244
0.84%
-163,896
0%
12/31/2017
BNP Paribas Asset Management Belgium SA
201,496
0.53%
0
0.02%
07/31/2018
Union Investment Privatfonds GmbH
165,273
0.43%
-78,125
0%
03/31/2018
NFU Mutual Investment Services Ltd.
144,912
0.38%
0
0.02%
06/30/2017
FundQuest Advisor
100,051
0.26%
0
0.21%
07/31/2018
Assenagon Asset Management SA (Germany)
72,982
0.19%
72,982
0%
06/29/2018
Inversis Gestión SGIIC SA
70,697
0.19%
34,091
0.34%
03/31/2018
Rothschild Asset Management SCS
54,806
0.14%
-17,500
0.01%
07/31/2018
Dimensional Fund Advisors Ltd.
42,361
0.11%
8,813
0%
11/30/2017
| Address |
Gaston Geenslaan 1
Leuven VL 3001
Belgium
|
|
Employees
|
- |
| Website |
http://www.oxurion.com |
| Updated |
07/08/2019 |
| ThromboGenics NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. It operates under JETREA (ocriplasmin) brand name. The company was founded by Desire Collen in 1991 and is headquartered in Leuven, Belgium. |
